XOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200 Day Moving Average - What's Next?

XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $24.29 and traded as high as $26.33. XOMA Royalty shares last traded at $26.22, with a volume of 158,454 shares traded.

Analyst Ratings Changes

XOMA has been the subject of several research analyst reports. Benchmark assumed coverage on shares of XOMA Royalty in a report on Thursday, April 17th. They issued a "buy" rating and a $35.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $104.00 target price on shares of XOMA Royalty in a report on Wednesday, May 28th. Finally, Wall Street Zen upgraded XOMA Royalty from a "hold" rating to a "buy" rating in a report on Saturday, June 14th.

XOMA Royalty Stock Up 0.6%

The firm has a market capitalization of $329.06 million, a P/E ratio of -23.90 and a beta of 0.94. The firm's 50-day moving average is $24.88 and its 200 day moving average is $24.31. The company has a debt-to-equity ratio of 1.18, a quick ratio of 5.54 and a current ratio of 5.54.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The business had revenue of $15.91 million during the quarter, compared to analysts' expectations of $6.75 million. As a group, equities research analysts predict that XOMA Royalty Corporation will post -1.41 EPS for the current fiscal year.

Insider Activity at XOMA Royalty

In other news, Director Joseph M. Limber bought 17,935 shares of the business's stock in a transaction that occurred on Thursday, April 3rd. The stock was acquired at an average cost of $25.24 per share, for a total transaction of $452,679.40. Following the purchase, the director now owns 16,524 shares of the company's stock, valued at approximately $417,065.76. This trade represents a -1,271.08% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CIO Bradley Sitko bought 2,000 shares of the business's stock in a transaction dated Monday, April 7th. The shares were bought at an average price of $24.70 per share, with a total value of $49,400.00. Following the purchase, the executive now owns 5,045 shares in the company, valued at $124,611.50. The trade was a 65.68% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 25,178 shares of company stock valued at $636,300. Insiders own 9.10% of the company's stock.

Institutional Trading of XOMA Royalty

A number of institutional investors have recently modified their holdings of XOMA. Woodline Partners LP raised its stake in XOMA Royalty by 7.9% in the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company's stock valued at $3,359,000 after purchasing an additional 12,284 shares in the last quarter. Stonepine Capital Management LLC boosted its position in shares of XOMA Royalty by 3.3% during the 1st quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company's stock worth $2,587,000 after acquiring an additional 4,113 shares in the last quarter. Nuveen LLC bought a new position in XOMA Royalty in the first quarter valued at approximately $286,000. Deutsche Bank AG raised its position in XOMA Royalty by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 6,309 shares in the last quarter. Finally, CM Management LLC raised its position in XOMA Royalty by 16.4% during the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock valued at $1,276,000 after purchasing an additional 9,000 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.